All In Biotech

Drug Trial Radar · NCT01040780

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

A Randomized,Double-blind,Multicenter Phase III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated With Chemotherapy

Last checked: Nov 19, 2026Latest source record: Feb 14, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 399 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

399

Actual

Start

Feb 2009

Primary completion

Mar 2010

Study completion Dec 2011

Sponsor

Sponsor type
Industry
First posted
Dec 30, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Icotinib is at least non-inferior to Gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients after one or two chemotherapies.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • IcotinibDrug

    125 mg three times daily (375 mg per day) by mouth

  • GefitinibDrug

    250 mg every 24 hours by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: 2-7 months

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-Yang Hospital

    Beijing, Beijing Municipality, China

  • Cancer Hospital, Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Bejing Cancer Hospital

    Beijing, Beijing Municipality, China

  • 307 Hospital of PLA

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Beijing Chest Hospital

    Beijing, Beijing Municipality, China

  • Third Affiliated Hospital, Third Military Medical University

    Chongqing, Chongqing Municipality, China

  • Guanghzou General Hospital of PLA

    Guangzhou, Guangdong, China

  • Guangdong General Hospital

    Guangzhou, Guangdong, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • Sun yat-sen Univerisity Cancer Center

    Guanzhou, Guangdong, China

  • the Second Xiangya Hospital,Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • 81 Hospital of PLA

    Nanjing, Jiangsu, China

  • Nanjing General Hospital of Nanjing Command,PLA

    Nanjing, Jiangsu, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • Ruijin Hospital,Shanghai Jiao-Tong University

    Shanghai, Shanghai Municipality, China

  • Zhongshan Hospital,Fudan University

    Shanghai, Shanghai Municipality, China

  • Changhai Hospital, Second Military Medical University

    Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Tangdu Hospital, Fourth Military Medical University

    Xi’an, Shanxi, China

  • Xijing Hospital, Fourth Military Medical University

    Xi’an, Shanxi, China

  • The First Affiliated Hospital of College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.